SpeeDx

SpeeDx is an Australian-based private molecular diagnostics company founded in 2009 in Sydney, New South Wales, specializing in multiplex PCR diagnostic technologies for sexually transmitted infections (STIs), respiratory pathogens, and other infectious diseases. The company developed the proprietary PlexZyme enzyme technology, which forms the foundation of its multiplexing platform, enabling multiple diagnostic targets to be detected simultaneously within a single test — achieving up to 12+ targets per well. SpeeDx's core product lines include STI diagnostic panels that detect infecting organisms alongside antimicrobial resistance markers, respiratory pathogen panels covering influenza A/B, RSV, and rhinoviruses, as well as enteric panels and custom research assay development. The company's technology runs on open molecular platforms commonly found in clinical reference laboratories, lowering adoption barriers. SpeeDx sells products in more than 19 countries and holds over 200 granted or pending patents. Beyond direct product sales, the company offers technology partnering, co-development, and custom assay development services for diagnostic companies and pharmaceutical firms.